Advertisement

The ASCO Post Newsreels help clinicians stay up to date on news in the world of clinical oncology and hematology. Newsreels feature leading authorities presenting high-impact clinical findings at major oncology meetings throughout the year.



Showing All Recent Newsreels Videos


Advertisement

2025 ASCO Annual Meeting

William G. Wierda, MD, PhD, on Fixed-Duration Ibrutinib and Venetoclax in First-Line CLL

William G. Wierda, MD, PhD, on Lisocabtagene Maraleucel in Relapsed/Refractory CLL: TRANSCEND CLL 004 

Giuseppe Curigliano, MD, PhD, on Patient-Reported Outcomes From EMBER-3

Nicholas C. Turner, MD, PhD, on INAVO120: Final Overall Survival Analysis

Constantine Si Lun Tam, MD, FRACP, FRCPA, MBBS, on CLL/SLL: First-Line Zanubrutinib Monotherapy in Patients With del(17p)

Christopher M. Booth, MD, on a Structured Exercise Program for Patients With Colon Cancer

Andrew Kuykendall, MD, on Hepcidin Mimetic for Polycythemia Vera

Stuart J. Wong, MD, on Adjuvant Regimen in Resected HNSCC

Nicholas C. Turner, MD, PhD, on Treating Emergent ESR1 Mutations in Advanced Breast Cancer

Raffaele Califano, MD, on EGFR-Mutant Advanced NSCLC: MARIPOSA-2

Yelena Y. Janjigian, MD, on Gastric/GEJ Cancer: Immunotherapy Plus FLOT

Mazyar Shadman, MD, PhD, on Doublet for Treatment-Naive CLL/SLL

Heinz-Josef Lenz, MD, on MSI-H/dMMR Metastatic Colorectal Cancer: Expanded Analyses From CheckMate 8HW

Clifford A. Hudis, MD, FASCO, FACP, on ASCO Guidelines Assistant

Andrew J. Armstrong, MD, MS, on ARCHES: 5-Year Overall Survival Follow-up

David Allen Barbie, MD, on Clinical and Molecular Features of Participants in the ADRIATIC Trial

Mafalda Oliveira, MD, PhD, on How Does Hyperglycemia Affect Treatment of Advanced Breast Cancer?

Arelis Esther Martir-Negron, MD, on Prevalence of BRCA Variants in Hispanic Residents of South Florida

Sara M. Tolaney, MD, MPH, FASCO, on PD-L1–Positive Advanced TNBC: First-Line Doublet Comparison

Elena Elez, MD, PhD, on Updated Survival Data From the BREAKWATER Trial

Karen Eubanks Jackson on Receiving the 2025 ASCO Patient Advocate Award

Manmeet Singh Ahluwalia, MD, MBA, FASCO, on Liquid Biopsy in Glioblastoma

Sameek Roychowdhury, MD, PhD, on Telemedicine in Clinical Trials

Angela R. Bradbury, MD, on Genetic Testing Approach in Patients With Metastatic Cancers

David R. Spigel, MD, FASCO, on NSCLC Treatment Planning: Role of 14-Gene Molecular Assay

Stephen K.L. Chia, MD, FRCPC, on Advanced HER2-Negative and ER-Positive Breast Cancer: SERD and AKT Inhibitor

Alicia Latham, MD, MS, on Using ctDNA to Detect Endometrial Cancer

Frank A. Sinicrope, MD, on Adjuvant Treatment Strategies for Stage III dMMR Colon Cancer

Martin Reck, MD, PhD, on Postsurgical MRD, Genomic Mutations, and Outcomes in Resectable NSCLC: AEGEAN Trial

Asaf Maoz, MD, on Pancreatic Surveillance Eligibility Criteria

Asaf Maoz, MD, on Li-Fraumeni Syndrome: Multimodality Screening Program 

Rami Manochakian, MD, FASCO, on Tarlatamab vs Chemotherapy for Second-Line Treatment of SCLC: Expert Point of View

Alicia K. Morgans, MD, MPH, FASCO, on How Does Androgen Receptor Inhibition Affect Quality of Life?

Nicholas D. James, PhD, FRCP, MBBS, on Using AI to Identify Benefit From Prostate Cancer Therapy

Bjorn Henning Gronberg, MD, PhD, on SCLC: Adjuvant Immunotherapy After CRT

Jamie E. Chaft, MD, FASCO, on Resectable EGFR-Mutated NSCLC: NeoADAURA Results

Shahzad Raza, MD, on Relapsed or Refractory AL Amyloidosis: First U.S. Trial of CAR T-Cell Therapy

Nitin Jain, MD, on Front-Line Therapies for CLL: Research Highlights From ASCO 2025

Luis G. Paz-Ares, MD, PhD, on IMforte Trial in Extensive-Stage SCLC

Luis G. Paz-Ares, MD, PhD, on Extensive-Stage SCLC: Comparison of First-Line Regimens

Suneel Deepak Kamath, MD, on Disparities in NIH and Federal Funding Across Different Cancer Types

Praful Ravi, MBBChir, MRCP, on High-Risk Localized Prostate Cancer: Docetaxel With ADT and Radiotherapy

Eric Huttenlocher Bent, MD, PhD, on Oligometastatic Prostate Cancer: Intensified Hormonal Blockade

Neil M. Iyengar, MD, on Cancer Risk Reduction: Effects of Menopausal HRT and GLP-1 RAs

Hope S. Rugo, MD, FASCO, and Rebecca Alexandra Dent, MD, FASCO, on Breast Cancer Data Highlights: Sequencing of Endocrine Therapy

Violaine Randrian, MD, PhD, on Lynch Syndrome, Genetics, and Immunotherapy

Ruben A. Mesa, MD, on Essential Thrombocythemia: SURPASS-ET Trial


2025 Tandem Meetings

Betty Hamilton, MD: Research Highlights in GVHD

Kristina Maas-Bauer, MD, on ROCK1/2 Inhibition and GVHD

John Magenau, MD, on Alpha-1-Antitrypsin for High-Risk Acute GVHD

Masumi Ueda Oshima, MD, on, a Posttransplant GVHD Prophylaxis Strategy


2025 ASCO GU

Benjamin Maughan, MD, PharmD, on Exercise Therapy for Patients With Advanced Prostate Cancer

Nicholas D. James, PhD, FRCP, MBBS, on an ADT Option: Transdermal Estradiol Patches

Omid Yazdanpanah, MD, on Metastatic Castration-Resistant Prostate Cancer: LuPSMA With or Without ARPIs

Masood Moghul, PhD, on a Mobile Prostate Cancer Clinical Unit: Findings From the Man Van

William Aronson, MD, on a Specialized Diet in Men on Active Surveillance for Prostate Cancer

Karim Fizazi, MD, PhD, on HRR-Deficient mCRPC: Final Overall Survival in TALAPRO-2

Neeraj Agarwal, MD, FASCO, on mCRPC: Talazoparib Plus Enzalutamide as First-Line Treatment

Michael Schweizer, MD: EZH2 Inhibitor Plus Enzalutamide in mCRPC


2025 ASCO GI

Aasma Shaukat, MD, MPH, on A Blood-Based Test for Colorectal Cancer Screening

Thierry André, MD, on First Results From CheckMate 8HW

Susumu Hijioka, MD, on the Phase III STARTER-NET Study in GEP-NET

Scott Kopetz, MD, PhD, FACP, on the BREAKWATER Study in BRAF V600–Mutant Metastatic Colorectal Cancer

Cathy Eng, MD, on the FRESCO-2 Study in Metastatic Colorectal Cancer

Anna Martling, MD, PhD, on the ALASCCA Trial in Colorectal Cancer


2024 SABCS

Sibylle Loibl, MD, PhD, on Primary Results of the Randomized, Phase III PADMA Study in HER2-Negative/HR-Positive Metastatic Breast Cancer

Mafalda Oliveira, MD, PhD, on Primary Results of SOLTI VALENTINE

Aditya Bardia, MD, on Destiny-Breast06: An Additional Analysis

Adrienne Waks, MD, on MARGOT/TBCRC052: Phase II Trial in HER2-Positive Breast Cancer

Nan Chen, MD, on Impact of Anthracyclines in High Genomic Risk Node-Negative HR-Positive/HER2-Negative Breast Cancer

Andrew Tutt, MB ChB, PhD, FMedSci, on OlympiA: High-Risk BRCA-Positive Breast Cancer

Jame Abraham, MD, FACP on the Phase III ZEST Trial

Jame Abraham, MD, FACP on the PATINA Trial

Komal Jhaveri, MD, FACP on The Phase III EMBER Trial

Sherko Kuemmel, MD on Final Survival Results From the WSG ADAPT-HR+/HER2-Negative Chemotherapy Trial


2024 JADPRO Live

Justin Arnall, PharmD, BCOP, FCCP, on Complicating “Factors”: When Malignancy and Non-Malignant Hematology Collide

Kathryn Newlin, RN, MSN, ANP-BC, on Updates in HR-Positive, HER2-Negative Metastatic Breast Cancer

Cara Norelli, MS, AGNP-C, on Managing Dermatologic Side Effects in Patients With Cancer


Thematic Newsreels

Ovarian Cancer 2024: Year at a Glance, Part 1

Ovarian Cancer 2024: Year-at-a-Glance, Part 2

Allison Betof Warner, MD, PhD, on TIL Therapy for Advanced Melanoma: Innovative Clinical Advances in Treatment


2024 ASH Annual Meeting

Nikolaos Katsivelos, MD, and John Levine, MD, MS, on How Serial Clinical and Biomarker Monitoring During Treatment Can Stratify Patients With Low-Risk GVHD

Maayan Levy, PhD, and Marco Ruella, MD, on How a Ketogenic Diet Enhances CAR T-Cell Antitumor Function Via Beta-Hydroxybutyrate (BHB)

Jennifer R. Brown, MD, PhD, on Fixed-Duration Acalabrutinib/Venetoclax in Fit Patients With CLL: AMPLIFY Trial

Anne Sophie Michallet, MD, PhD, on MRD-Guided vs Standard Combination Therapy for Select Untreated Patients With CLL

Danielle Wolfe Cohen, MD, on Mechanisms of Relapse in B-Cell Acute Lymphoblastic Leukemia

Nitin Jain, MD, on First-Line Treatment With Pirtobrutinib-Based Regimen in CLL

Rachel E. Rau, MD, and Sumit Gupta, MD, PhD, on Pediatric B-Cell ALL: Blinatumomab Added to Chemotherapy in Newly Diagnosed Disease

Timothy S. Fenske, MD, on Lack of Benefit of Autologous Hematopoietic Cell Transplantation in Mantle Cell Lymphoma Patients in First Complete Remission With Undetectable Minimal Residual Disease

John O. Mascarenhas, MD, on Relapsed/Refractory Myelofibrosis: Navtemadlin vs Best Available Therapy After JAK Inhibitor Treatment

John O. Mascarenhas, MD, on Myelofibrosis: Novel Combination of Imetelstat Plus Ruxolitinib

Matthew S. Davids, MD, MMSc, on Triplet Therapy of Acalabrutinib, Venetoclax, and Obinutuzumab: Focus on TP53-Aberrant CLL

Jenny Paredes, PhD, on How Increased Fiber Intake Results in Better Overall Survival and Lower GI-aGVHD in Allo-HCT Recipients and Pre-Clinical GVHD Models

Natalie Wuliji, DO, and Mohamed Sorror, MD, MSc, on the Impact of Socioeconomic Factors on Access to and Outcomes of Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: A Multi-Center Observational Study

Hannah Choe, MD, on Dynamics of Overall and Organ-Specific Responses to Axatilimab in Chronic Graft-Versus-Host Disease: Analysis from the AGAVE-201 Study

Erik Thiele Orberg, MD, PhD, on Recovery of the Intestinal Microbiome in Patients at Day +100 after Allogeneic Stem Cell Transplantation Is Defined by Microbial Metabolite Profiles and Linked to Long-Term Outcomes


42nd Annual Chemotherapy Foundation Symposium

Vered Stearns, MD, on Shifting Patient Outcomes: Updates in Triple-Negative Breast Cancer

Komal Jhaveri, MD, FACP, on Antibody-Drug Conjugates in Breast Cancer

Tiffany Traina, MD, FASCO, on Advances in the Treatment of HR-Positive Breast Cancer


Lynn Sage Breast Cancer Symposium 2024

Frederick Howard, MD, on the Role of Targeted Therapy and Endocrine Therapy in the Patient With Breast Cancer

Charles E. Geyer, Jr, MD, FACP, on Management of the Patient With HER2-Positive Breast Cancer in 2024

Sunil S. Badve, MD, FRCPath, on Tumor-Infiltrating Lymphocytes in the Patient With Breast Cancer

William Gradishar, MD, on Advances in Endocrine Therapeutic Options for Patients With ER-Positive, HER2-Negative Breast Cancer


Timely Topics

Julie Gralow, MD, FACP, FASCO, on Conserving IV Fluid Supplies During Natural Disasters


ESMO Congress 2024

Ghassan K. Abou-Alfa, MD, MBA, FASCO, and Lorenza Rimassa, MD, on Unresectable Hepatocellular Carcinoma: 5-Year Overall Survival Results From the HIMALAYA Trial

Ghassan K. Abou-Alfa, MD, MBA, FASCO, and Lorenza Rimassa, MD, on Doublet Immunotherapy Options for Unresectable Hepatocellular Carcinoma

Josep M. Llovet, MD, PhD, on Intermediate-Stage Hepatocellular Carcinoma: Addition of Lenvatinib Plus Pembrolizumab to TACE

Josep M. Llovet, MD, PhD, on Treatment Options in Hepatocellular Carcinoma

Rachna T. Shroff, MD, MS, FASCO, on Advanced Hepatocellular Carcinoma: Anlotinib Plus Penpulimab vs Sorafenib

Maeve Lowery, MD, on a Novel Bifunctional Antibody in Advanced Hepatocellular Carcinoma


IBC East 2024

Paolo Tarantino, MD, on the Current and Future Landscape of Antibody-Drug Conjugates

Joseph A. Sparano, MD, FACP, on Premenopausal HR-positive Early Breast Cancer: What to Do Outside the OFSET Trial?

Kristin Rojas, MD, FACS, on Improving Sexual Health During Breast Cancer Treatment


IBC West 2024

Aditya Bardia, MD, MPH, FASCO, on the Current and Future Landscape of Antibody-Drug Conjugates

Heather McArthur, MD, MPH, on Immunotherapy for High-Risk, Early-Stage Breast Cancer

Aditya Bardia, MD, MPH, FASCO, on Novel Therapies Targeting the Estrogen Receptor

Sara A. Hurvitz, MD, FACP, on New Therapeutic Strategies for HER2-Positive Metastatic Disease Including Brain Metastases

Advertisement

Advertisement




Jun
12
Today In Oncology
FDA Approves Taletrectinib for ROS1-Positive Non-Small Cell Lung Cancer
MRD-Guided Treatment in Newly Diagnosed Multiple Myeloma
Study Reports Increasing Incidence Rates of Appendiceal Adenocarcinoma in Those Born After 1945
Adjuvant Cemiplimab in High-Risk Cutaneous Squamous Cell Carcinoma
Self-Collection Kit Mailings May Increase Cervical Cancer Screening Rates in Underserved Settings
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo